The University of Chicago Header Logo

Connection

Mark J. Ratain to Drug Hypersensitivity

Back to Details
This is a "connection" page, showing publications Mark J. Ratain has written about Drug Hypersensitivity.
Mark J. Ratain
Connection Strength
0.063
Drug Hypersensitivity
  1. Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest New Drugs. 2004 Nov; 22(4):449-58.
    View in: PubMed
    Score: 0.063
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.